Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2023-09-11 00:00:00 ET · period of report 2023-09-07 · accession 0001209191-23-048905 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-11 | 2023-09-07 | RARE | Huizenga Theodore Alan | SVP, CAO | M - OptEx | $21.00 | +2,000 | 25.8K | +8% | +$42.0K |
| DM | 2023-09-11 | 2023-09-07 | RARE | Huizenga Theodore Alan | SVP, CAO | S - Sale+OE | $40.80 | -2,163 | 23.6K | -8% | -$88.2K |
| D | 2023-09-11 | 2023-09-07 | RARE | Huizenga Theodore Alan | SVP, CAO | M - OptEx | $0.00 | -2,000 | 3,000 | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-07 | M | A | 2,000 | $21.00 | 25,777 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. |
| 2 | Common | Common Stock | 2023-09-07 | S | D | 2,000 | $41.00 | 23,777 | D | — | — | |
| 3 | Common | Common Stock | 2023-09-07 | S | D | 163 | $38.34 | 23,614 | D | — | — | (F2) Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-09-07 | M | D | 2,000 | $0.00 | 3,000 | D | $21.00 · — to 2024-01-29 | 2,000 Common Stock | (F3) 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. |